Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Flamel Technologies, a France-based biopharmaceutical company engaged in the development of polymer-based delivery technologies for medical applications, has appointed Jeffery Vick as its new chief business officer.
Subscribe to our email newsletter
Mr Vick previously served as CEO of Silence Therapeutics, a European RNAi company. He received his MBA from Stanford University, his MS in chemistry from the University of California, San Diego, and brings to Flamel over 20 years experience in the pharmaceutical and biotechnology industries.
Stephen Willard, CEO of Flamel, said: “Jeff’s expertise in corporate development, market research and intellectual property issues has been developed both in Europe and in the US. His background in these areas, together with his history of doing fundamental research in oncology and his work in developing biotechnology, drug delivery and genomics companies, makes him an ideal addition to the Flamel team.”